INTRODUCTION
Anaplastic thyroid carcinoma (ATC) is the least common but most lethal of thyroid cancers, with an overall median survival time of less than 6 months from diagnosis. Anecdotic cases of longterm survivors have been reported, mainly in patients with intrathyroid tumors at the time of surgical treatment [1] . All patients are classified as stage IV, with the primary lesion restricted to the thyroid gland in stage IVA; locoregional lymph nodes may exist in IVA/IVB, whereas stage IVC disease is defined by distant metastases [2 & ]. Distant metastases (median percentage) are seen in lung (37.2%), mediastinum (25%), liver (10.1%), bone (6.4%), kidney (5.3%), heart and adrenals (5.2%), and brain (4.4%) [3] . Causes of death are mainly attributed to distant metastases in 51.5% (range 12-68%), local complications in 23.7% (5-37%), or both in 26.2% of patients (25-51%) [3] .
The sudden onset, explosive and often dramatic evolution of ATC necessitates immediate involvement by surgeons, radiation oncologists, medical oncologists, and palliative care teams [4 && ]. An early multidisciplinary approach is recommended to reach consensus over the realistic treatment options that can be offered to the patient to timely improve effectiveness of care and reduce inconsistent decisions in favor of clearly established goals of care [4 && ]. To date, there is no standard therapy for ATC, approximately 10% of patients with ATC present with only an intrathyroidal tumor, whereas 40% have extrathyroidal invasion and/or lymph node metastasis, with the remainder of patients presenting with widely metastatic disease [4 && ]. The rationale for a total or near-total thyroidectomy is that approximately 20% of patients with ATC have coexisting differentiated thyroid cancer, and a complete resection is associated with improved diseasefree survival and overall survival (OS) with or without combination chemotherapy and radiotherapy [4 The median survival time of patients with ATC without distant metastases at the time of initial diagnosis is approximately 6 months [5] .
Conversely, median survival time for relapse following either surgery and or radiation with or without chemotherapy (corresponds to previously treated, advanced regional disease) or metastatic disease is about 3-5 months. In the majority of cases the only option is palliative chemotherapy with an objective response rate of 5%, though a response rate of 20% has been reported for the most active agent (doxorubicin).
According to retrospective studies the most important factors associated with longer survival are completeness of surgical resection (achievable in only a minority of patients) and high-dose (>40 Gy) external beam radiotherapy (preferably intensity modulated radiation therapy) [2 & ]. Specifically, R0 (negative surgical margin), R1 (gross resection, positive microscopic margin), or 'complete' resections resulted in substantially improved median and 1-3-year survival [2 & ]. Neoadjuvant therapy has also allowed some patients to convert from unresectable to resectable disease and should be considered in selected patients [2 & ]. Radiotherapy has been shown to reduce morbidity and mortality from locoregional complications and, in consequence, it should be used regardless of surgical resectability [2 & ]. In a Japanese experience, age at least 70 years, presence of acute symptoms, leukocytosis (white blood cell count 10 000/ml), large tumor greater than 5 cm, T4b tumor, and distant metastasis were identified as significant risk factors for lower survival [6] .
TUMOR BIOLOGY
Recent evidence showed that BRAF is involved in the development of papillary thyroid carcinoma (PTC) and in the progression of ATC. As such, BRAF represents an attractive target in thyroid cancer [7] . The BRAF oncogene, part of the RAS-RAF-MEK-ERK signal transduction pathway, is mutated to its active form in up to 24% of ATC cases and is thought to be an important event in the evolution of ATC [8] .
In addition, a progressive activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway and an associated methylation of phosphatase and tensin homolog, which suppress this pathway, were found in thyroid adenomas, follicular and anaplastic thyroid cancers (ATC) [9] . Similarly, the deregulation of TP53 (tumor protein p53) and Wnt pathways and mutations of b-catenin are common in both poorly differentiated thyroid cancer and ATC [10] .
Until now, only a limited number of ATC have been investigated for mRNA expression, with incomplete and sometimes not very sensitive microarray sets.
ATC frequently derives from PTC, which are usually considered to have a good prognosis. A recent study showed that ATC and PTC have largely overlapping mRNA expression profiles, with most genes regulated in ATC being also regulated in several PTC. These findings further corroborate the fact that most ATC may derive from PTC. However, a molecular signature of aggressiveness composed of nine genes can clearly distinguish between the two tumors [11 & ]. Following these discoveries, new molecules are emerging in the treatment of metastatic ATC ( Table 1 ). The aim of this review is to sum up the most significant agents that are currently being developed in the literature for the treatment of metastatic ATC.
NEW DRUGS
Among the new drugs, proteasome and Aurora kinase inhibitors were demonstrated to be effective in both preclinical and clinical investigations [12] . Bortezomib, a proteasome inhibitor, was shown to reduce tumor cell proliferation and increase apoptosis of ATC cells in vitro [13, 14] . In addition, a case report of second-line treatment with bortezomib induced necrosis in the relapsed tumor mass in a patient suffering from ATC.
Aurora kinases are proteins which are implicated in the regulation of multiple aspects of chromosome segregation during the mitotic phase of the cell cycle. They are overexpressed in many human thyroid tissues and their degradation at the end of the mitosis is determined by the ubiquitin-proteasome pathway. Previous studies showed that MLN8054 alone, as well as other Aurora kinase inhibitors, such as VX-680 [15] or AZD1152 [16] , had proapoptotic and antiproliferative effects in ATC cell lines. These findings strongly suggest the possibility that Aurora
KEY POINTS
The anaplastic thyroid cancer (ATC) patient necessitates immediate multidisciplinary approach for individualized treatment.
No standard treatment is approved for metastatic ATC.
Target therapy is under investigation.
Clinical research in this very rare and aggressive tumor is challenging.
kinase inhibitors could be used in the treatment of ATC and, likely, in other thyroid cancer not responsive to conventional therapies. In a recent study, the authors demonstrated that the combination of bortezomib and Aurora kinase inhibitors was able to determine an antitumoral activity in three ATC cell lines, especially by reducing the cell growth rate and inducing cell apoptosis [12] . They demonstrated a synergistic effect of the combination of these two drugs which are directed against two different targets both very important for the inhibition of the cell cycle progression [12] . This is one of the first studies that used a combination of targeted drugs, as all the other studies currently available in the literature considered the efficacy of just one molecule.
Another new molecule that has been recently investigated is chrysin, which demonstrated inhibition of cell growth by activation of the Notch1 signaling pathway in ATC cells both in vitro and in vivo [17] . These findings suggest that activation of Notch1 signaling is worthy of further investigations as a treatment option for ATC patients. As such, novel Notch1 inducers are promising therapeutic candidates that should be further evaluated [17] .
The largest prospective randomized multicenter open-label trial conducted in metastatic ATC evaluated the therapeutic role of combretastatin-A4, which is a novel vascular targeting agent able to block neoangiogenesis. Eighty out of 180 planned patients were randomized to receive up to six cycles of carboplatin and paclitaxel with CA4P (CA4P arm) or without CA4P (control arm) [18 && ]. The targeted sample size of 180 patients was not reached due to slow enrollment. After six cycles of therapy, patients on the CA4P arm without progression could continue to receive CA4P until disease progression. The primary objective of this study was OS. Secondary objectives included safety, 1-year survival, and progression-free survival. Seventy-five of the 80 randomized patients received treatment with a median (min, max) follow-up of 4.7 (0.1, 32.6) months. All deaths were due to disease progression except two patients whose deaths were attributed to disease-related complications. The median survival time for the CA4P arm was 5.2 months versus 4.0 months for the control arm, resulting in a hazard ratio and 95% confidence interval (CI) of 0.65 (0.38-1.10) based on the intent-to-treat analysis. This would suggest a 35% reduction in the risk of death. One-year survival was 27% on the CA4P arm versus 9% on the control arm (P 1/4 0.065, Fisher's exact test). Grade 1-2 hypertension and grade 3-4 neutropenia were more common on the CA4P arm. This trial suggested that CA4P improves OS, with a three-fold higher 1-year survival rate; however, the improvement was not statistically significant. The regimen was well tolerated, with adverse events and deaths primarily related to ATC and disease progression [18 && ]. The primary end point of OS benefit was not reached, likely due to limited numbers of participants enrolled. The authors of the study suggested that, in order to allow optimal inclusion into new trials, future ambitious ATC phase III studies could consider having fewer cardiac and other restrictions, given the bad prognosis of these patients with standard treatment. Currently, a phase I/II trial of crolibulin (EPC2407), a derivative of combretastatin, and cisplatin is recruiting patients (www. clinicaltrials.gov identifier NCT01240590).
Other trials with targeted agents were based on limited numbers of patients, but some have yielded interesting results. Sorafenib is a tyrosine kinase inhibitor which acts on raf-1 serine/threonine kinase. The BRAF oncogene mutated to its active form in up to 24% of ATC cases. A multi-institutional phase II trial with sorafenib 400 mg twice daily was conducted and the results were comparable to the previous study conducted by the same authors with fosbretabulin [19] . This is a phase II trial to determine the efficacy and safety of fosbretabulin in patients with advanced ATC; this study showed that there were no objective responses [19] . However, the subgroup of ATC that occurs in the setting of anaplastic transformation of a more well differentiated thyroid cancer or those ATC presenting with histological regions of papillary differentiation may respond to sorafenib [20 && ]. The role of pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, as a potential drug to treat ATC was also evaluated. A recent work showed that despite displaying evidence of in-vivo antitumor activity, pazopanib demonstrated only minimal activity in human ATC [21 && ].
Even if these two studies [20 && ,21 && ] failed to demonstrate a significant activity of sorafenib and pazopanib this latter is under investigation in combination. Specifically in ATC, a randomized, doubleblind clinical trial was designed to evaluate the effectiveness of pazopanib to increase the clinical activity of paclitaxel therapy when administered in conjunction with locoregional intensity modulated radiotherapy (www. clinicaltrials.gov identifier NCT01236549).
Other emerging agents are the anaplastic lymphoma kinase (ALK) kinase inhibitors. ALK is a member of the insulin receptor subfamily of receptor tyrosine kinases (RTKs) and its encoding gene is located on the short arm of chromosome 2. In a recent study conducted in ATC, two novel point mutations were identified: C3592T and G3602A, in exon 23 of the ALK gene, with a prevalence of 11.11%, but no mutations were found in the matched normal tissues or in well differentiated thyroid cancers. These two mutations, resulting in L1198F and G1201E amino acid changes, respectively, both reside within the ALK tyrosine kinase domain where they dramatically increased tyrosine kinase activities.
Similarly, these mutations heightened the ability of ALK to activate the PI3K/Akt and mitogenactivated protein (MAP) kinase pathways in established mouse cells. Further investigations showed that these two ALK mutants strongly promoted cell focus formation, anchorage-independent growth, and cell invasion [22 & ]. Two other clinical trials on ATC have been recently completed: a phase 1/2 dose finding study of an experimental new drug CS7017, an oral peroxisome proliferator-activated receptor gamma agonist taken by mouth twice daily in combination with paclitaxel chemotherapy (www. clinicaltrials.gov identifier NCT00603941) and a trial evaluating imatinib in ATC (www.clinicaltrials.gov identifier NCT00115739). The results of these two trials have not been published yet. Virotherapies are of interest in the treatment for ATC. They include the restoration of the sodium iodide symporter (NIS), suicide therapy or oncolytic viruses that are conditionally replicative only within tumor cells [23] . A recent work validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic measles virus (MV-Edm), modified to include the NIS gene. These data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease [24] .
CONCLUSION
The rarity of the disease prevents the accumulation of data demonstrating survival prolongation or quality-of-life improvement in ATC patients in response to treatment with systemic therapies. Moreover, the extremely rapid disease evolution makes the criteria for entering the protocol often prohibitive, thus further restricting patient inclusion. This, apart from the need of multi-institutional and global efforts to allow adequate accrual, will have to be considered in the development of new drugs such as biological agents, in this disease.
In everyday practice, risks and benefits should be carefully weighted and considered in the context of each patient, in order to individualize treatments according to patient needs and expectations [4 && ].
